Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization

References

• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-9. doi:10.1038/nature10673. PMID:22193102
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227-42. doi:10.1038/nri3405. PMID:23470321
   PubMed Web of Science ®Google Scholar
• Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer. 2014;2:7. doi:10.1186/2051-1426-2-7. PMID:24855562
   PubMedGoogle Scholar
• Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, Sakaguchi S, Ishikawa I, Azuma M. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol. 2004;172:7306-14. doi:10.4049/jimmunol.172.12.7306
   PubMed Web of Science ®Google Scholar
• He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol. 2013;191:4174-83. doi:10.4049/jimmunol.1300409
   PubMed Web of Science ®Google Scholar
• Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2007;2:61-5. doi:10.1016/j.uct.2007.06.001. PMID:19587842
   PubMedGoogle Scholar
• Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333:1030-4. doi:10.1126/science.1206954. PMID:21852502
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 2011;187:1754-63. doi:10.4049/jimmunol.1101135
   PubMed Web of Science ®Google Scholar
• Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci U S A. 2012;109:10966-71. doi:10.1073/pnas.1208698109. PMID:22723355
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, Yee S, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 2011;19:101-13. doi:10.1016/j.ccr.2010.11.012. PMID:21251615
   PubMed Web of Science ®Google Scholar
• Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 2003;171:562-8. doi:10.4049/jimmunol.171.2.562
   PubMed Web of Science ®Google Scholar
• Zhang D, Goldberg MV, Chiu ML. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody. J Biol Chem. 2016;291:27134-46. doi:10.1074/jbc.M116.757773. PMID:27856634
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685-93. doi:10.1084/jem.20130573. PMID: 23897982
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92:475-80. doi:10.1038/icb.2014.26. PMID:24732076
   PubMed Web of Science ®Google Scholar
• Simons PJ, Boon L, Luo J, Brezski RJ, Goldberg M. Humanized anti-CD134 (OX40) antibodies and uses thereof. 2014. Patent US 2014/0377284 A1, WO 2014/ 148895 A1
   Google Scholar
• Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem. 1998;273:5808-14. doi:10.1074/jbc.273.10.5808. PMID:9488716
   PubMed Web of Science ®Google Scholar
• Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012;61:1721-33. doi:10.1007/s00262-012-1237-1. PMID:22406983
   PubMed Web of Science ®Google Scholar
• Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, González-Muñoz A, Parmentier J, Black C, Soden J, et al. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget. 2016;7:68278-91. doi:10.18632/oncotarget.11943. PMID: 27626702
   PubMed Web of Science ®Google Scholar
• Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol. 2008;45:3926-33. doi:10.1016/j.molimm.2008.06.027. PMID:18691763
   PubMed Web of Science ®Google Scholar
• Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K. Engineered antibody Fc variant with selectively enhanced FcgammaRIIb binding over both FcgammaRIIa(R131) and FcgammaRIIa(H131). Protein Eng Des Sel. 2013;26:589-98. doi:10.1093/protein/gzt022
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260-3. doi:10.1126/science.1248943. PMID:24626930
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293:1155-9. doi:10.1126/science.1061692. PMID:11498595
   PubMed Web of Science ®Google Scholar
• Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol. 2007;368:767-79. doi:10.1016/j.jmb.2007.02.034. PMID:17368483
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126-32. doi:10.1107/S0907444904019158. PMID:15572765
   PubMed Web of Science ®Google Scholar
• The PyMOL Molecular Graphics System. Version 1.8 Schrödinger, LLC. https://www.pymol.org/citing
   Google Scholar
• Teplyakov A, Zhao Y, Malia TJ, Obmolova G, Gilliland GL. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface. Mol Immunol. 2013;56:131-9. doi:10.1016/j.molimm.2013.03.018. PMID:23628091
   PubMed Web of Science ®Google Scholar
• Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods. 2014;65:114-26. doi:10.1016/j.ymeth.2013.06.035. PMID:23872058
   PubMed Web of Science ®Google Scholar
• Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. 2007;121:392-404. doi:10.1111/j.1365-2567.2007.02588.x. PMID:17386079
   PubMed Web of Science ®Google Scholar
• Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372:379-83. doi:10.1038/372379a0. PMID:7969498
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Cook KE, Li Q, Gao C, Wu H, Dall'Acqua WF. Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem. 2014;289:7812-24. doi:10.1074/jbc.M113.537563. PMID:24469444
   PubMed Web of Science ®Google Scholar
• Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2:599. doi:10.1038/ncomms1608. PMID:22186895
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs. 2013;5:397-405
   PubMed Web of Science ®Google Scholar
• Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759-69. doi:10.1093/intimm/dxl110. PMID:17077181
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Nanami M, Ishigai M. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica; the fate of foreign compounds in biological systems. 2014;44:1127-34. doi:10.3109/00498254.2014.941963. PMID:25030041
   PubMed Web of Science ®Google Scholar
• Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8:1064-78. doi:10.1080/19420862.2016.1193660. PMID:27232760
   PubMed Web of Science ®Google Scholar
• Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 2015;22:1727-41. doi:10.1038/cdd.2015.109. PMID:26292758
   PubMed Web of Science ®Google Scholar
• Davies AM, Jefferis R, Sutton BJ. Crystal structure of deglycosylated human IgG4-Fc. Mol Immunol. 2014;62:46-53. doi:10.1016/j.molimm.2014.05.015. PMID:24956411
   PubMed Web of Science ®Google Scholar
• Davies AM, Rispens T, Ooijevaar-de Heer P, Gould HJ, Jefferis R, Aalberse RC, Sutton BJ. Structural determinants of unique properties of human IgG4-Fc. J Mol Biol. 2014;426:630-44. doi:10.1016/j.jmb.2013.10.039. PMID:24211234
   PubMed Web of Science ®Google Scholar
• Kiyoshi M, Caaveiro JM, Kawai T, Tashiro S, Ide T, Asaoka Y, Hatayama K, Tsumoto K. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun 2015;6:6866. doi:10.1038/ncomms7866. PMID:25925696
   PubMed Web of Science ®Google Scholar
• Wu Y, West AP, Jr., Kim HJ, Thornton ME, Ward AB, Bjorkman PJ. Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12. Cell Rep. 2013;5:1443-55. doi:10.1016/j.celrep.2013.11.015. PMID:24316082
   PubMed Web of Science ®Google Scholar
• Frank M, Walker RC, Lanzilotta WN, Prestegard JH, Barb AW. Immunoglobulin G1 Fc domain motions: implications for Fc engineering. J Mol Biol. 2014;426:1799-811. doi:10.1016/j.jmb.2014.01.011. PMID:24522230
   PubMed Web of Science ®Google Scholar
• Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003;325:979-89. doi:10.1016/S0022-2836(02)01250-0. PMID:12527303
   PubMed Web of Science ®Google Scholar
• Luo Y, Lu Z, Raso SW, Entrican C, Tangarone B. Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors. MAbs. 2009;1:491-504. doi:10.4161/mabs.1.5.9631. PMID:20065648
   PubMed Web of Science ®Google Scholar
• Stubenrauch K, Wessels U, Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J Pharm Biomed Anal. 2009;49:1003-8. doi:10.1016/j.jpba.2009.01.030. PMID:19250787
   PubMed Web of Science ®Google Scholar
• Kabsch W Xds. Acta crystallographica Section D, Biological crystallography. 2010;66:125-132. doi:10.1107/S0907444909047337. PMID:20124692
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658-74. doi:10.1107/S0021889807021206. PMID:19461840
   PubMed Web of Science ®Google Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011;67:235-42. doi:10.1107/S0907444910045749. PMID:21460441
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000;164:4178-84. doi:10.4049/jimmunol.164.8.4178
   PubMed Web of Science ®Google Scholar
• Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213-21. doi:10.1107/S0907444909052925. PMID:20124702
   PubMed Web of Science ®Google Scholar
• Joosten RP, Long F, Murshudov GN, Perrakis A. The PDB_REDO server for macromolecular structure model optimization. IUCrJ. 2014;1:213-20. doi:10.1107/S2052252514009324. PMID:25075342
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67:355-67. doi:10.1107/S0907444911001314. PMID:21460454
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28:235-42. doi:10.1093/nar/28.1.235. PMID:10592235
   PubMed Web of Science ®Google Scholar